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Rectal cancer is the fifth most frequent cancer in both sexes
combined in England and Wales (Quinn et al, 2001). It is less
common than colon cancer, but incidence trends during the 1990s
were similar (Coleman et al, 1999). Improvements in survival have
been slower in the United Kingdom than elsewhere in western
Europe (Sant et al, 2001; Finn-Faivre et al, 2002; Martijn et al,
2003). There was a substantial deprivation gradient in survival for
patients diagnosed with rectal cancer in England and Wales up to
1990, with patients in the most affluent group having 1-year and
5-year relative survival 5–7% higher than those in the most
deprived group, even after adjustment for differences and trends in
background mortality between these socioeconomic groups
(Coleman et al, 1999).
Almost 156000 patients were registered with cancer of the
rectum (rectum (ICD-10 C20) and rectosigmoid junction (C19)) in
England and Wales during the 14-year period 1986–1999, with a
male–female sex ratio of 1.4 (range 1.3–1.6 between the eight
English regions and Wales). Annual incidence rates in each
deprivation category ranged from 16 to 20 per 100000 during the
1990s, with no clear socioeconomic gradient. The proportion of
rectal tumours recorded as adenocarcinoma increased from 65 to
75% by 1999, but a commensurate fall in the proportion of
poorly specified carcinomas (from 25 to 15%) suggests that the
quality of pathology data has improved, and the true proportion
of adenocarcinoma was approximately 75% throughout the
1990s. Squamous carcinoma represented 4% of rectal tumours,
unchanged since the late 1980s. Information on the stage of rectal
cancer at diagnosis was not available in the national cancer registry
before 1995, and stage-specific analyses for the period 1986–1999
were thus not possible. Approximately 7% of patients (regional
range 2–12%) who were otherwise eligible for analysis were
excluded because they were registered solely from a death
certificate, so their duration of survival was unknown (zero
recorded survival: date of diagnosis the same as the date of death).
The proportion of cases with zero recorded survival was similar in
all socioeconomic groups (5–6%, data not shown), however, so
exclusions from analysis are unlikely to have had any impact on
socioeconomic gradients in survival, or on changes in that gradient
with time. The vital status of 2% of patients was unknown, and a
further 3% were excluded because the rectal cancer was not their
first primary malignancy. In all, 132602 patients were included in
the analyses (87.8% of those eligible).
SURVIVAL TRENDS
One-year, 5-year and 10-year relative survival rose substantially and
significantly in both sexes between 1986–1990 and 1996–1999, by an
average of 5–8% every 5 years, after adjustment for deprivation
(Table 1). The increase in 5-year survival was particularly marked
between the early and late 1990s, in both sexes.
Short-term predictions of survival for patients diagnosed during
2000–2001, using hybrid analysis (Brenner and Rachet, 2004), do
not suggest any substantial improvement in the near future
(Table 1, Figure 1).
DEPRIVATION
Survival increased for men and women in all deprivation groups to
the end of the 1990s, but the increase was smaller in the more
deprived groups in both sexes, and the deprivation gap in survival
widened as a result (Table 2, Figure 2). Trends in the deprivation
gap over time were similar in both sexes. For patients diagnosed
during 1986–1990 and 1996–1999, respectively, the deprivation
gap in 5-year relative survival widened from  5% to  9% in men
(weighted average change  2.4% every 5 years) and from  4% to
 8% in women ( 2.5% every 5 years), even after adjustment for
increasing differences in background mortality between the
deprivation groups. Short-term prediction with hybrid analysis
suggests that the widening of the deprivation gap is likely to
continue in the near future (Table 2).
COMMENTS
There has been a dramatic improvement in rectal cancer
survival over the last 15 years, particularly during the 1990s.
Substantial advances in rectal cancer management have occurred
during the last two decades. Earlier diagnosis has allowed
more effective treatment (increase in resection rates, especially
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www.bjcancer.comsphincter-saving procedures) and a substantial reduction
in operative mortality (Finn-Faivre et al, 2002; Mitry et al,
2002). Major new developments have also taken place in
treatment, including total mesorectal excision and adjuvant
radiotherapy (Kapiteijn et al, 2002; Martijn et al, 2003). Together,
these are likely to explain the increasing overall trends in survival.
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 67.5 (66.9, 68.2) 70.6 (70.1, 71.2) 75.2 (74.6, 75.7) 5.2** (4.0, 6.4) 75.8 (75.0, 76.6)
Women 66.2 (65.5, 66.9) 70.6 (69.9, 71.3) 74.7 (74.0, 75.4) 5.5** (4.1, 6.9) 75.6 (74.6, 76.6)
5 years Men 37.8 (37.1, 38.6) 41.1 (40.5, 41.8) 48.7 (47.8, 49.6) 7.4** (5.8, 8.9) 49.8 (48.8, 50.9)
Women 39.4 (38.6, 40.2) 44.3 (43.5, 45.1) 51.3 (50.3, 52.4) 8.1** (6.3, 10.0) 52.3 (51.0, 53.5)
10 years Men 32.1 (31.3, 32.9) 35.4 (34.5, 36.3) 7.4** (4.3, 10.5) 43.6 (42.3, 44.9)
Women 34.2 (33.4, 35.1) 40.3 (39.4, 41.3) 7.4** (4.0, 10.8) 47.9 (46.4, 49.3)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival estimated
with cohort or complete approach (1986–1990, 1991–1995, 1996–1999)
or hybrid approach (2000–2001) (see Rachet et al,2 0 0 8 ) .
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Figure 2 Trends in the deprivation gap in 5-year relative survival (%)
by sex and calendar period of diagnosis: England and Wales,
adults (15–99 years) diagnosed during 1986–1999 and followed up
to 2001.
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British Journal of Cancer (2008) 99(S1), S30–S32 & 2008 Cancer Research UKImprovements in survival in England and Wales have been more
marked than for colon cancer, but, as for colon cancer,
improvements have mainly been confined to patients in the most
affluent groups. The deprivation gradient in rectal cancer survival
(8–9% at 5 years) is greater than for colon cancer, and the
significant increase seen during the 1990s suggests that the most
deprived patients have not benefited equally from the optimal
treatment currently available.
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  5.4** ( 7.3,  3.6)  4.8** ( 6.4,  3.1)  8.1** ( 9.7,  6.4)  1.4* ( 2.7,  0.1)  9.7* ( 12.0,  7.4)
Women  4.6** ( 6.7,  2.5)  4.4** ( 6.4,  2.5)  6.9** ( 9.0,  4.9)  1.2 ( 2.8, 0.3)  5.7* ( 8.5,  2.9)
5 years Men  4.7** ( 6.8,  2.6)  6.0** ( 8.0,  4.0)  9.4** ( 12.0,  6.8)  2.4** ( 4.1,  0.6)  9.8* ( 13.0,  6.7)
Women  3.7** ( 6.1,  1.3)  6.7** ( 9.0,  4.3)  8.3** ( 11.4,  5.2)  2.5* ( 4.5,  0.5)  9.4* ( 13.1,  5.7)
10 years Men  3.6** ( 6.0,  1.3)  8.7** ( 11.3,  6.2)  5.1** ( 8.5,  1.7)  11.2* ( 14.9,  7.5)
Women  3.9** ( 6.5,  1.4)  5.8** ( 8.6,  3.0)  1.9 ( 5.7, 1.9)  7.9* ( 12.1,  3.6)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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